Long non-coding RNA LINC00649 regulates YES-associated protein 1 (YAP1)/Hippo pathway to accelerate gastric cancer (GC) progression via sequestering miR-16-5p

References

• Li Y, Jiang T, Zhou W, et al. Pan-cancer characterization of immune-related lncRNAs identifies potential oncogenic biomarkers. Nat Commun. 2020;11(1):1000.
   PubMed Web of Science ®Google Scholar
• Fattahi S, Kosari-Monfared M, Golpour M, et al. LncRNAs as potential diagnostic and prognostic biomarkers in gastric cancer: a novel approach to personalized medicine. J Cell Physiol. 2020;235(4):3189–3206.
   PubMed Web of Science ®Google Scholar
• Pan H, Ding Y, Jiang Y, et al. LncRNA LIFR-AS1 promotes proliferation and invasion of gastric cancer cell via miR-29a-3p/COL1A2 axis. Cancer Cell Int. 2021;21(1):7.
   PubMed Web of Science ®Google Scholar
• Piao HY, Guo S, Wang Y, et al. Exosome-transmitted lncRNA PCGEM1 promotes invasive and metastasis in gastric cancer by maintaining the stability of SNAI1. Clin Transl Oncol. 2021;23(2):246–256.
   PubMed Web of Science ®Google Scholar
• Dai Q, Zhang T, Pan J, et al. LncRNA UCA1 promotes cisplatin resistance in gastric cancer via recruiting EZH2 and activating PI3K/AKT pathway. J Cancer. 2020;11(13):3882–3892.
   PubMed Web of Science ®Google Scholar
• Li M, Zhang YY, Shang J, et al. LncRNA SNHG5 promotes cisplatin resistance in gastric cancer via inhibiting cell apoptosis. Eur Rev Med Pharmacol Sci. 2019;23(10):4185–4191.
   PubMed Web of Science ®Google Scholar
• Qiao XL, Zhong ZL, Dong Y, et al. LncRNA HMGA1P4 promotes cisplatin-resistance in gastric cancer. Eur Rev Med Pharmacol Sci. 2020;24(17):8830–8836.
   PubMed Web of Science ®Google Scholar
• Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm. Cancer Res. 2017;77(15):3965–3981.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Tang L. The application of lncRNAs in cancer treatment and diagnosis. Recent Pat Anticancer Drug Discov. 2018;13(3):292–301.
   PubMed Web of Science ®Google Scholar
• Guo C, Gao YY, Ju QQ, et al. LINC00649 underexpression is an adverse prognostic marker in acute myeloid leukemia. BMC Cancer. 2020;20(1):841.
   PubMed Web of Science ®Google Scholar
• Guo C, Ju QQ, Zhang CX, et al. Overexpression of HOXA10 is associated with unfavorable prognosis of acute myeloid leukemia. BMC Cancer. 2020;20(1):586.
   PubMed Web of Science ®Google Scholar
• Ye G, Guo L, Xing Y, et al. Identification of prognostic biomarkers of prostate cancer with long non-coding RNA-mediated competitive endogenous RNA network. Exp Ther Med. 2019;17(4):3035–3040.
   PubMed Web of Science ®Google Scholar
• He M, Lin Y, Xu Y. Identification of prognostic biomarkers in colorectal cancer using a long non-coding RNA-mediated competitive endogenous RNA network. Oncol Lett. 2019;17(3):2687–2694.
   PubMed Web of Science ®Google Scholar
• Chen Y, Lin Y, Shu Y, et al. Interaction between N6-methyladenosine (m6A) modification and noncoding RNAs in cancer. Mol Cancer. 2020;19(1):94.
   PubMed Web of Science ®Google Scholar
• Janaki Ramaiah M, Divyapriya K, Kartik Kumar S, et al. Drug-induced modifications and modulations of microRNAs and long non-coding RNAs for future therapy against glioblastoma multiforme. Gene. 2020;723:144126.
   PubMed Web of Science ®Google Scholar
• Sun T, Wu Z, Wang X, et al. LNC942 promoting METTL14-mediated m6A methylation in breast cancer cell proliferation and progression. Oncogene. 2020;39(31):5358–5372.
   PubMed Web of Science ®Google Scholar
• Braga EA, Fridman MV, Moscovtsev AA, et al. LncRNAs in ovarian cancer progression, metastasis, and main pathways: ceRNA and alternative mechanisms. Int J Mol Sci. 2020;21(22):8855.
   PubMed Web of Science ®Google Scholar
• Qi M, Yu B, Yu H, et al. Integrated analysis of a ceRNA network reveals potential prognostic lncRNAs in gastric cancer. Cancer Med. 2020;9(5):1798–1817.
   PubMed Web of Science ®Google Scholar
• Ruan L, Qian X. MiR-16-5p inhibits breast cancer by reducing AKT3 to restrain NF-κB pathway. Biosci Rep. 2019;39(8). DOI:10.1042/BSR20191611
   Google Scholar
• Wu H, Wei M, Jiang X, et al. lncRNA PVT1 promotes tumorigenesis of colorectal cancer by stabilizing miR-16-5p and Interacting with the VEGFA/VEGFR1/AKT axis. Mol Ther Nucleic Acids. 2020;20:438–450.
   PubMedGoogle Scholar
• Peng Q, Chen Y, Li CN. Long noncoding RNA Linc00210 promotes non-small cell lung cancer progression via sponging miR-16-5p/PTK2 axis. Eur Rev Med Pharmacol Sci. 2020;24(18):9438–9452.
   PubMed Web of Science ®Google Scholar
• Li Z, Suo B, Long G, et al. Exosomal miRNA-16-5p derived from M1 macrophages enhances T cell-dependent immune response by regulating PD-L1 in gastric cancer. Front Cell Dev Biol. 2020;8:572689.
   PubMed Web of Science ®Google Scholar
• Zhang J, Song Y, Zhang C, et al. Circulating MiR-16-5p and MiR-19b-3p as two novel potential biomarkers to indicate progression of gastric cancer. Theranostics. 2015;5(7):733–745.
   PubMed Web of Science ®Google Scholar
• Zhu C, Huang Q, Zhu H. Melatonin inhibits the proliferation of gastric cancer cells through regulating the miR-16-5p-Smad3 pathway. DNA Cell Biol. 2018;37(3):244–252.
   PubMed Web of Science ®Google Scholar
• Liu Z, Wang Y, Wang L, et al. Long non-coding RNA AGAP2-AS1, functioning as a competitive endogenous RNA, upregulates ANXA11 expression by sponging miR-16-5p and promotes proliferation and metastasis in hepatocellular carcinoma. J Exp Clin Cancer Res. 2019;38(1):194.
   PubMed Web of Science ®Google Scholar
• Tao Y, Yue P, Miao Y, et al. The lncRNA MEG3/miR-16-5p/VGLL4 regulatory axis is involved in etoposide-induced senescence of tumor cells. J Gene Med. 2021;23(2):e3291.
   PubMed Web of Science ®Google Scholar
• Driskill JH, Pan D. The Hippo pathway in liver homeostasis and pathophysiology. Annu Rev Pathol. 2021;16(1):299–322.
   PubMed Web of Science ®Google Scholar
• Xie Z, Wang Y, Yang G, et al. The role of the Hippo pathway in the pathogenesis of inflammatory bowel disease. Cell Death Dis. 2021;12(1):79.
   PubMed Web of Science ®Google Scholar
• Moloudizargari M, Asghari MH, Nabavi SF, et al. Targeting Hippo signaling pathway by phytochemicals in cancer therapy. Semin Cancer Biol. 2020. DOI:10.1016/j.semcancer.2020.05.005
   PubMed Web of Science ®Google Scholar
• Samji P, Rajendran MK, Warrier VP, et al. Regulation of Hippo signaling pathway in cancer: a MicroRNA perspective. Cell Signal. 2021;78:109858.
   PubMed Web of Science ®Google Scholar
• Holden JK, Cunningham CN. Targeting the Hippo pathway and cancer through the TEAD family of transcription factors. Cancers (Basel). 2018;10(3):81.
   PubMed Web of Science ®Google Scholar
• Mo JS, Park HW, Guan KL. The Hippo signaling pathway in stem cell biology and cancer. EMBO Rep. 2014;15(6):642–656.
   PubMed Web of Science ®Google Scholar
• Hum M, Tan HJ, Yang Y, et al. WBP2 promotes gastric cancer cell migration via novel targeting of LATS2 kinase in the Hippo tumor suppressor pathway. Faseb J. 2021;35(2):e21290.
   PubMed Web of Science ®Google Scholar
• Kang W, Huang T, Zhou Y, et al. miR-375 is involved in Hippo pathway by targeting YAP1/TEAD4-CTGF axis in gastric carcinogenesis. Cell Death Dis. 2018;9(2):92.
   PubMed Web of Science ®Google Scholar
• Kim SH, Jin H, Meng RY, et al. Activating Hippo pathway via Rassf1 by ursolic acid suppresses the tumorigenesis of gastric cancer. Int J Mol Sci. 2019;20(19). DOI:10.3390/ijms20184439
   Web of Science ®Google Scholar
• He S, Zhang H, Xiao Z, et al. The interaction of TEA domain transcription factor 4 (TEAD4) and Yes-associated protein 1 (YAP1) promoted the malignant process mediated by serum/glucocorticoid regulated kinase 1 (SGK1). Bioengineered. 2021;12(1):601–614.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Bauden M, Andersson R, et al. YAP1 is an independent prognostic marker in pancreatic cancer and associated with extracellular matrix remodeling. J Transl Med. 2020;18(1):77.
   PubMed Web of Science ®Google Scholar
• Tsuji T, Ozasa H, Aoki W, et al. YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation. Nat Commun. 2020;11(1):74.
   PubMed Web of Science ®Google Scholar
• Liu H, Liu Y, Bian Z, et al. Circular RNA YAP1 inhibits the proliferation and invasion of gastric cancer cells by regulating the miR-367-5p/p27 Kip1 axis. Mol Cancer. 2018;17(1):151.
   PubMed Web of Science ®Google Scholar
• Ajani JA, Xu Y, Huo L, et al. YAP1 mediates gastric adenocarcinoma peritoneal metastases that are attenuated by YAP1 inhibition. Gut. 2021;70(1):55–66.
   PubMed Web of Science ®Google Scholar
• Wang J, Huang F, Shi Y, et al. RP11-323N12.5 promotes the malignancy and immunosuppression of human gastric cancer by increasing YAP1 transcription. Gastric Cancer. 2021;24(1):85–102.
   PubMed Web of Science ®Google Scholar
• An L, Nie P, Chen M, et al. MST4 kinase suppresses gastric tumorigenesis by limiting YAP activation via a non-canonical pathway. J Exp Med. 2020;217(6). DOI:10.1084/jem.20191817
   Web of Science ®Google Scholar
• Dong X, Yang Z, Yang H, et al. Long non-coding RNA MIR4435-2HG promotes colorectal cancer proliferation and metastasis through miR-206/YAP1 axis. Front Oncol. 2020;10:160.
   PubMed Web of Science ®Google Scholar
• Jin Z, Chen B. LncRNA ZEB1-AS1 regulates colorectal cancer cells by MiR-205/YAP1 axis. Open Med (Wars). 2020;15(1):175–184.
   PubMedGoogle Scholar
• Coggins GE, Farrel A, Rathi KS, et al. YAP1 mediates resistance to MEK1/2 inhibition in neuroblastomas with hyperactivated RAS signaling. Cancer Res. 2019;79(24):6204–6214.
   PubMed Web of Science ®Google Scholar
• Gao F, Wu H, Wang R, et al. MicroRNA-485-5p suppresses the proliferation, migration and invasion of small cell lung cancer cells by targeting flotillin-2. Bioengineered. 2019;10(1):1–12.
   PubMed Web of Science ®Google Scholar
• Gao W, Gao J, Chen L, et al. Targeting XIST induced apoptosis of human osteosarcoma cells by activation of NF-kB/PUMA signal. Bioengineered. 2019;10(1):261–270.
   PubMed Web of Science ®Google Scholar
• Chen L, Wang X, Ji C, et al. MiR-506-3p suppresses papillary thyroid cancer cells tumorigenesis by targeting YAP1. Pathol Res Pract. 2020;216(12):153231.
   PubMed Web of Science ®Google Scholar
• He J, Su X, Xie W. MiR-582-3p alleviates osteoarthritis progression by targeting YAP1. Mol Immunol. 2020;128:258–267.
   PubMed Web of Science ®Google Scholar